相关实验视频
Updated: Sep 10, 2025

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
348
在远程体重控制计划中使用西马格卢提德和蒂尔泽帕提德:计划补充者的回顾性12个月结果
Becky Richards1, Will Lunt1, Michael Whitman1
1Second Nature, 483 Green Lanes, London, GB.
JMIR formative research
|August 21, 2025
概括
远程使用类似葡萄糖-1受体激活剂 (GLP-1RA) 程序显示肥胖症的显著减肥. 与传统护理相比, 这些数字化干预措施是有效的,可行的和节省成本的.
科学领域:
- 肥胖药物
- 数字卫生干预措施
- 药物质量管理
背景情况:
- 肥胖影响全球超过8.9亿成年人, 传统的干预措施往往长期失败.
- 葡萄糖类-1受体激动剂 (GLP-1RAs) 显示显著的体重减轻,但专家的访问受到成本和能力的限制.
研究的目的:
- 评估12个月远程GLP-1RA支持的减肥计划的有效性,可行性,可接受性和成本效益.
- 在这个远程程序中比较tirzepatide和semaglutide的结果.
主要方法:
- 在12个月的远程体重控制计划中,对339名参与者进行了回顾性分析,使用了tirzepatide或semaglutide.
- 计划结合药物,基于应用程序的支持,营养师指导和临床监督,
- 主要结果:平均体重变化和≥10%和≥15%的体重减轻;次要结果:行为变化,副作用,可接受性,可行性和成本效益.
主要成果:
- 在12个月的平均体重减轻为- 22. 9公斤与蒂尔泽帕提德和- 18. 1公斤与西马格卢提德 (P<0. 05).
- 体重减轻率为95. 2% (蒂尔泽帕提德) 和83. 1% (西马格卢提德);体重减轻率分别为83. 7%和56. 2%.
- 观察到不活动和初始副作用 (恶心,疲劳,便秘) 的显著减少,没有副作用的报道增加.
结论:
- 远程交付的GLP-1RA程序实现了与临床试验相比的体重减轻,并且比传统的英国服务节省了大量成本 (10-70%).
- 蒂尔泽帕提德和西马格卢提德都显示出具有临床意义的减肥,具有良好的安全性和积极的行为变化.
- 在资源有限的系统中,数字化治疗模式是可行的和有效的.
相关概念视频
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Antidepressant Drugs: MAOIs and Other Agents
344
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
344
Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
Insulin: Dosing Regimen and Adverse Effects
257
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
257
Oral Hypoglycemic Agents: Biguanides and Glitazones
291
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
291
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
202
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
202

